iNtRON Biotechnology, Inc. (048530.KQ)

KRW 5500.0

(-4.35%)

Total Debt Summary of iNtRON Biotechnology, Inc.

iNtRON Biotechnology, Inc.'s latest annual total debt in 2023 was 402.9 Million KRW , down -98.71% from previous year.
iNtRON Biotechnology, Inc.'s latest quarterly total debt in 2024 Q2 was 419.17 Million KRW , down -8.13% from previous quarter.
iNtRON Biotechnology, Inc. reported annual total debt of 31.27 Billion KRW in 2022, down -31.66% from previous year.
iNtRON Biotechnology, Inc. reported annual total debt of 45.75 Billion KRW in 2021, up 336.88% from previous year.
iNtRON Biotechnology, Inc. reported quarterly total debt of 456.25 Million KRW for 2024 Q1, up 13.24% from previous quarter.
iNtRON Biotechnology, Inc. reported quarterly total debt of 428.11 Million KRW for 2023 Q3, down -98.73% from previous quarter.

Annual Total Debt Chart of iNtRON Biotechnology, Inc. (2023 - 2012)

Historical Annual Total Debt of iNtRON Biotechnology, Inc. (2023 - 2012)

Year	Total Debt	Total Debt Growth
2023	402.9 Million KRW	-98.71%
2022	31.27 Billion KRW	-31.66%
2021	45.75 Billion KRW	336.88%
2020	10.47 Billion KRW	-47.1%
2019	19.79 Billion KRW	379.08%
2018	4.13 Billion KRW	-9.15%
2017	4.54 Billion KRW	57.56%
2016	2.88 Billion KRW	-16.52%
2015	3.45 Billion KRW	0.0%
2012	- KRW	0.0%

Year	Total Debt	Total Debt Growth
2024 Q2	419.17 Million KRW	-8.13%
2024 Q1	456.25 Million KRW	13.24%
2023 Q3	428.11 Million KRW	-98.73%
2023 Q1	32.1 Billion KRW	2.68%
2023 FY	402.9 Million KRW	-98.71%
2023 Q2	33.71 Billion KRW	5.02%
2023 Q4	402.9 Million KRW	-5.89%
2022 FY	31.27 Billion KRW	-31.66%
2022 Q4	31.27 Billion KRW	5.82%
2022 Q3	29.55 Billion KRW	-0.49%
2022 Q2	29.69 Billion KRW	-36.51%
2022 Q1	46.77 Billion KRW	2.22%
2021 Q3	44.52 Billion KRW	909.08%
2021 Q4	45.75 Billion KRW	2.75%
2021 FY	45.75 Billion KRW	336.88%
2021 Q1	4.08 Billion KRW	-59.27%
2021 Q2	4.41 Billion KRW	8.03%
2020 FY	10.47 Billion KRW	-47.1%
2020 Q1	14.44 Billion KRW	-2.21%
2020 Q4	10.02 Billion KRW	-4.59%
2020 Q3	10.51 Billion KRW	-20.3%
2020 Q2	13.18 Billion KRW	-8.67%
2019 Q3	14.52 Billion KRW	1.51%
2019 FY	19.79 Billion KRW	379.08%
2019 Q1	4.6 Billion KRW	11.36%
2019 Q4	14.76 Billion KRW	1.64%
2019 Q2	14.31 Billion KRW	211.06%
2018 Q4	4.13 Billion KRW	-1.94%
2018 FY	4.13 Billion KRW	-9.15%
2018 Q3	4.21 Billion KRW	-1.9%
2018 Q2	4.29 Billion KRW	-1.87%
2018 Q1	4.37 Billion KRW	-3.75%
2017 Q1	2.84 Billion KRW	-1.54%
2017 FY	4.54 Billion KRW	57.56%
2017 Q4	4.54 Billion KRW	-19.6%
2017 Q3	5.65 Billion KRW	-1.89%
2017 Q2	5.76 Billion KRW	102.86%
2016 Q4	2.88 Billion KRW	0.0%
2016 Q1	- KRW	0.0%
2016 FY	2.88 Billion KRW	-16.52%
2015 FY	3.45 Billion KRW	0.0%
2013 Q3	4.23 Billion KRW	-4.88%
2013 Q2	4.45 Billion KRW	-6.59%
2013 Q1	4.77 Billion KRW	0.0%
2012 FY	- KRW	0.0%
2012 Q4	- KRW	0.0%
2012 Q3	- KRW	0.0%

Peer Total Debt Comparison of iNtRON Biotechnology, Inc.

Name	Total Debt	Total Debt Difference
HLB Co., Ltd.	62.7 Billion KRW	99.357%
BINEX Co., Ltd.	53.5 Billion KRW	99.247%
Bioneer Corporation	44.63 Billion KRW	99.097%
Anterogen.Co.,Ltd.	9.74 Billion KRW	95.864%
MEDIPOST Co., Ltd.	52.33 Billion KRW	99.23%
CrystalGenomics, Inc.	32 Billion USD	98.741%
Helixmith Co., Ltd	20.22 Billion KRW	98.008%
Chabiotech Co.,Ltd.	449.63 Billion KRW	99.91%
Medy-Tox Inc.	82.83 Billion KRW	99.514%
Peptron, Inc.	9.13 Billion KRW	95.588%
Amicogen, Inc.	149.59 Billion KRW	99.731%
Genexine, Inc.	67.42 Billion KRW	99.402%
HLB Therapeutics Co.,Ltd.	10.02 Billion KRW	95.98%
LegoChem Biosciences, Inc.	12.64 Billion KRW	96.813%
ALTEOGEN Inc.	83.76 Billion KRW	99.519%
PharmaResearch Co., Ltd.	34.3 Billion KRW	98.826%
SillaJen, Inc.	9.69 Billion KRW	95.845%
JETEMA, Co., Ltd.	130.49 Billion KRW	99.691%
OliX Pharmaceuticals,Inc	39.35 Billion KRW	98.976%
Genomictree Inc.	1.83 Billion KRW	78.039%
MedPacto, Inc.	8.6 Billion KRW	95.317%
D&D Pharmatech	8.13 Billion KRW	95.047%
EASY BIO,Inc.	82.27 Billion KRW	99.51%
GI Innovation, Inc.	3.72 Billion KRW	89.172%